EyePoint, Inc. is a clinical stage biopharmaceutical company focused on developing therapeutics for serious retinal diseases. The company uses its proprietary bioerodible Durasert E technology to enable sustained intraocular drug delivery. Its lead product candidate DURAVYU combines the small molecule inhibitor vorolanib with the Durasert E platform to target vascular endothelial growth factor mediated retinal diseases. DURAVYU is being evaluated in phase three trials for…
EyePoint, Inc. is a clinical stage biopharmaceutical company focused on developing therapeutics for serious retinal diseases. The company uses its proprietary bioerodible Durasert E technology to enable sustained intraocular drug delivery. Its lead product candidate DURAVYU combines the small molecule inhibitor vorolanib with the Durasert E platform to target vascular endothelial growth factor mediated retinal diseases. DURAVYU is being evaluated in phase three trials for wet age related macular degeneration and diabetic macular edema. Additional preclinical programs evaluate razoprotafib formulated in Durasert E. The company is headquartered in Watertown Massachusetts and operates a commercial manufacturing facility in Northbridge Massachusetts. Its technology has been used in four FDA approved products that utilize a non erodible formulation of the Durasert platform.
EyePoint generates revenue primarily from licensing its drug delivery technology and product candidates to partners. The company receives upfront payments milestone payments and royalties on net sales from licensed products. For example it has licensed YUTIQ to ANI for an upfront payment of $75 million and is entitled to additional royalties. It also has agreements with Equinox and Betta concerning vorolanib. Additionally the company manufactures and supplies certain products to partners generating further revenue.
EyePoint occupies a niche in the ophthalmology market as a developer of sustained delivery therapies for retinal diseases. It faces competition from established anti VEGF agents such as Lucentis Eylea Vabysmo and Beovu as well as their biosimilars. These competitors require frequent intravitreal injections while EyePoint aims to offer less frequent dosing through its durable implant. The company's differentiated approach combines VEGF inhibition with anti inflammatory activity via vorolanib which may provide advantage over single mechanism therapies. Additionally its proprietary Durasert technology already has FDA approved products demonstrating a proven track record in drug delivery.
The company serves patients suffering from retinal conditions such as wet age related macular degeneration and diabetic macular edema. Physicians who administer intravitreal injections are the direct customers for its therapeutic products. EyePoint also works with pharmaceutical partners including ANI Ocumension Equinox and Betta which license its technology or co develop product candidates.